FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916864575> ?p ?o ?g. }

• W2916864575 endingPage "3100" @default.
• W2916864575 startingPage "3100" @default.
• W2916864575 abstract "Abstract Background : Chronic myelomonocytic leukemia (CMML), a myeloid neoplasm with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms (MPN), is characterized by peripheral blood (PB) monocytosis and a risk for leukemic transformation (LT). Gene mutations commonly seen in CMML include, TET2 (~60%), SRSF2 (~50%) and ASXL1 (~40%). MPN associated-driver mutations such as JAK2V617F (~10%), MPL (<1%) and CALR (<1%) are uncommon, and in fact, the 2016 World Health Organization (WHO) guidelines state that the presence of these mutations tends to support a diagnosis of MPN with monocytosis. We carried out this study to assess the i) clinical correlates and ii) survival outcomes of MPN associated-driver mutations in CMML. Methods : 323 molecularly annotated patients with WHO-defined CMML were included in the study. All patients had bone marrow (BM) biopsies and cytogenetics performed at diagnosis. Targeted capture assays were carried out on BM DNA specimens obtained at diagnosis for 30 myeloid relevant genes, by previously described methods. Results: Among the 323 study patients, 67% were males and median age was 71 years (range, 18-95). Twenty five (8%) patients had CMML with MPN associated-driver mutations; 24 (96%) with JAK2V617F and 1(4%) with a MPLW515L mutation. There were no patients with CALR or JAK2 exon 12 mutations. Additional signal-pathway mutations included NRAS (15%), KRAS (4%), CBL (14%), PTPN11 (3%), CSF3R (1%), and SH2B3 (<1%). i) Phenotypic correlates: The median age of CMML patients with MPN-associated driver mutations was 71 years and 66% were male. The WHO morphological subtypes included CMML-0 60%, CMML-1 24% and CMML-2 16%; while 91% of patients had a normal karyotype. The distribution of mutations included TET2 75%, SRSF2 54%, ASXL1 48%, RUNX1 20%, NRAS and EZH2 12% each, SETBP1 8%, SF3B1, U2AF1, CBL, PTPN11, FLT3-TKD, & Tp53 4% each, respectively. Risk stratification by the Mayo Molecular Model included high 16%, intermediate-2 32%, intermediate-1 36% and low risk 16%, respectively. In comparison to CMML patients without MPN associated-driver mutations, those with, had a higher hemoglobin (HB, p=0.001) and hematocrit (p=0.001), were more likely to have leukocytosis (p=0.02) and elevated LDH levels (p=0.0002), less likely to have thrombocytopenia (p=0.003), more likely to have a proliferative CMML phenotype (p=0.01) with palpable splenomegaly (p=0.0007), and more likely to have mutations involving TET2 (p=0.02). Six (2%) thrombotic events were documented in the cohort; 2 (8%) in patients with MPN-driver mutations and 4 (1%) in those without (p=0.07). There were no differences between the two groups with regards to the degree of monocytosis, PB and BM blasts, BM cellularity, BM megakaryocytic atypia, and BM fibrosis. ii) Survival outcomes: At last follow up 219 (68%) deaths and 55 (17%) LT were documented, of which 14 (56%) deaths and 2 (8%) LT occurred in the MPN-driver mutation group. The median OS for the entire cohort was 28 months (22-32); 31 months for CMML patients with MPN associated-driver mutations and 24 months for those without (p=0.4). On a univariate analysis, survival was adversely impacted by low HB (p<0.0001), high white blood count (p=0.0009) and absolute monocyte count (p=0.0004), circulating immature myeloid cells (p=0.02) and blasts (p=0.005), BM blasts (p=0.02), palpable splenomegaly (p=0.03), abnormal karyotype (p=0.001), presence of DNMT3A (p=0.006), ASXL1 (p=0.009), EZH2 (p=0.03) and Tp53 (p=0.02) mutations and the absence of TET2 (p=0.0009) mutations. Survival was not affected by the presence of JAK2V617F (p=0.4) or MPL (p=0.46) mutations. On a multivariable analysis that included the aforementioned significant variables, only HB <10 gm/dl (p=0.0016), presence of PB blasts (p=0.01), presence of DNMT3A (p=0.003) and the absence of TET2 mutations (p=0.02) retained significance. The presence of MPN associated-driver mutations did not impact LFS (p=0.36). Conclusions: The occurrence of MPN associated-driver mutations in CMML is infrequent (~8%) and is largely restricted to JAK2V617F. CMML patients with MPN-associated driver mutations have a higher HB/hematocrit, are more likely to have proliferative features and palpable splenomegaly, and are less likely to be thrombocytopenic. There was a trend towards an increased thrombotic risk, with no impact of these mutations on overall and leukemia free survival. Disclosures No relevant conflicts of interest to declare." @default.
• W2916864575 created "2019-03-02" @default.
• W2916864575 creator A5002643270 @default.
• W2916864575 creator A5006929029 @default.
• W2916864575 creator A5012298768 @default.
• W2916864575 creator A5016216479 @default.
• W2916864575 creator A5024612499 @default.
• W2916864575 creator A5063876159 @default.
• W2916864575 creator A5065054067 @default.
• W2916864575 creator A5072463255 @default.
• W2916864575 creator A5078452873 @default.
• W2916864575 creator A5079007941 @default.
• W2916864575 creator A5080965667 @default.
• W2916864575 date "2018-11-29" @default.
• W2916864575 modified "2023-09-30" @default.
• W2916864575 title "Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations" @default.
• W2916864575 doi "https://doi.org/10.1182/blood-2018-99-117335" @default.
• W2916864575 hasPublicationYear "2018" @default.
• W2916864575 type Work @default.
• W2916864575 sameAs 2916864575 @default.
• W2916864575 citedByCount "0" @default.
• W2916864575 crossrefType "journal-article" @default.
• W2916864575 hasAuthorship W2916864575A5002643270 @default.
• W2916864575 hasAuthorship W2916864575A5006929029 @default.
• W2916864575 hasAuthorship W2916864575A5012298768 @default.
• W2916864575 hasAuthorship W2916864575A5016216479 @default.
• W2916864575 hasAuthorship W2916864575A5024612499 @default.
• W2916864575 hasAuthorship W2916864575A5063876159 @default.
• W2916864575 hasAuthorship W2916864575A5065054067 @default.
• W2916864575 hasAuthorship W2916864575A5072463255 @default.
• W2916864575 hasAuthorship W2916864575A5078452873 @default.
• W2916864575 hasAuthorship W2916864575A5079007941 @default.
• W2916864575 hasAuthorship W2916864575A5080965667 @default.
• W2916864575 hasBestOaLocation W29168645751 @default.
• W2916864575 hasConcept C104317684 @default.
• W2916864575 hasConcept C121608353 @default.
• W2916864575 hasConcept C126322002 @default.
• W2916864575 hasConcept C143998085 @default.
• W2916864575 hasConcept C21790070 @default.
• W2916864575 hasConcept C2777928532 @default.
• W2916864575 hasConcept C2778923028 @default.
• W2916864575 hasConcept C2779282312 @default.
• W2916864575 hasConcept C2780007613 @default.
• W2916864575 hasConcept C2780076729 @default.
• W2916864575 hasConcept C2780240888 @default.
• W2916864575 hasConcept C2780817109 @default.
• W2916864575 hasConcept C2781087989 @default.
• W2916864575 hasConcept C2781107747 @default.
• W2916864575 hasConcept C2781187634 @default.
• W2916864575 hasConcept C2994225774 @default.
• W2916864575 hasConcept C501734568 @default.
• W2916864575 hasConcept C526805850 @default.
• W2916864575 hasConcept C54355233 @default.
• W2916864575 hasConcept C71924100 @default.
• W2916864575 hasConcept C86803240 @default.
• W2916864575 hasConceptScore W2916864575C104317684 @default.
• W2916864575 hasConceptScore W2916864575C121608353 @default.
• W2916864575 hasConceptScore W2916864575C126322002 @default.
• W2916864575 hasConceptScore W2916864575C143998085 @default.
• W2916864575 hasConceptScore W2916864575C21790070 @default.
• W2916864575 hasConceptScore W2916864575C2777928532 @default.
• W2916864575 hasConceptScore W2916864575C2778923028 @default.
• W2916864575 hasConceptScore W2916864575C2779282312 @default.
• W2916864575 hasConceptScore W2916864575C2780007613 @default.
• W2916864575 hasConceptScore W2916864575C2780076729 @default.
• W2916864575 hasConceptScore W2916864575C2780240888 @default.
• W2916864575 hasConceptScore W2916864575C2780817109 @default.
• W2916864575 hasConceptScore W2916864575C2781087989 @default.
• W2916864575 hasConceptScore W2916864575C2781107747 @default.
• W2916864575 hasConceptScore W2916864575C2781187634 @default.
• W2916864575 hasConceptScore W2916864575C2994225774 @default.
• W2916864575 hasConceptScore W2916864575C501734568 @default.
• W2916864575 hasConceptScore W2916864575C526805850 @default.
• W2916864575 hasConceptScore W2916864575C54355233 @default.
• W2916864575 hasConceptScore W2916864575C71924100 @default.
• W2916864575 hasConceptScore W2916864575C86803240 @default.
• W2916864575 hasIssue "Supplement 1" @default.
• W2916864575 hasLocation W29168645751 @default.
• W2916864575 hasOpenAccess W2916864575 @default.
• W2916864575 hasPrimaryLocation W29168645751 @default.
• W2916864575 hasRelatedWork W2040108927 @default.
• W2916864575 hasRelatedWork W2901682003 @default.
• W2916864575 hasRelatedWork W2916864575 @default.
• W2916864575 hasRelatedWork W2980099483 @default.
• W2916864575 hasRelatedWork W2983174944 @default.
• W2916864575 hasRelatedWork W2995213882 @default.
• W2916864575 hasRelatedWork W3211457947 @default.
• W2916864575 hasRelatedWork W3214403426 @default.
• W2916864575 hasRelatedWork W4295102849 @default.
• W2916864575 hasRelatedWork W4313544853 @default.
• W2916864575 hasVolume "132" @default.
• W2916864575 isParatext "false" @default.
• W2916864575 isRetracted "false" @default.
• W2916864575 magId "2916864575" @default.
• W2916864575 workType "article" @default.